191 related articles for article (PubMed ID: 32853708)
1. Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease.
Jackson WC; Tang M; Maurino C; Mendiratta-Lala M; Parikh ND; Matuszak MM; Dow JS; Cao Y; Mayo CS; Ten Haken RK; Schipper MJ; Cuneo KC; Owen D; Lawrence TS
Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):212-219. PubMed ID: 32853708
[TBL] [Abstract][Full Text] [Related]
2. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
[TBL] [Abstract][Full Text] [Related]
3. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
[TBL] [Abstract][Full Text] [Related]
4. The Potential for Midtreatment Albumin-Bilirubin (ALBI) Score to Individualize Liver Stereotactic Body Radiation Therapy.
Jackson WC; Hartman HE; Gharzai LA; Maurino C; Karnak DM; Mendiratta-Lala M; Parikh ND; Mayo CS; Haken RKT; Schipper MJ; Cuneo KC; Lawrence TS
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):127-134. PubMed ID: 33878421
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
[TBL] [Abstract][Full Text] [Related]
6. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
[TBL] [Abstract][Full Text] [Related]
9. A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.
Jackson WC; Suresh K; Maurino C; Feng M; Cuneo KC; Ten Haken RK; Lawrence TS; Schipper MJ; Owen D
Radiother Oncol; 2019 Dec; 141():101-107. PubMed ID: 31431377
[TBL] [Abstract][Full Text] [Related]
10. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
Gkika E; Schultheiss M; Bettinger D; Maruschke L; Neeff HP; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Radiat Oncol; 2017 Jul; 12(1):116. PubMed ID: 28701219
[TBL] [Abstract][Full Text] [Related]
11. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy.
Su TS; Yang HM; Zhou Y; Huang Y; Liang P; Cheng T; Chen L; Li LQ; Liang SX
Radiat Oncol; 2019 Mar; 14(1):50. PubMed ID: 30917853
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
[TBL] [Abstract][Full Text] [Related]
15. Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis.
Daniell KM; Banson KM; Diamond BH; Sioshansi S
Curr Treat Options Oncol; 2022 Dec; 23(12):1761-1774. PubMed ID: 36333623
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration.
Lee S; Kim H; Ji Y; Cho B; Kim SS; Jung J; Kwak J; Park JH; Lee SW; Kim JH; Yoon SM
Sci Rep; 2018 Nov; 8(1):16224. PubMed ID: 30385839
[TBL] [Abstract][Full Text] [Related]
17. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.
Cárdenes HR; Price TR; Perkins SM; Maluccio M; Kwo P; Breen TE; Henderson MA; Schefter TE; Tudor K; Deluca J; Johnstone PA
Clin Transl Oncol; 2010 Mar; 12(3):218-25. PubMed ID: 20231127
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
19. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
